Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
199
datasets available to search
ShareScore release 0.9.0
Dataset results
199 results for “case report”
COVID19 Flow-Maps Daily Cases Reports
<p>This repository contains COVID-19 data for Spain, including daily cases at the level of autonomous communities as well as provinces, and higher spatial resolution for several autonomous communities (eight out of the nineteen autonomous communities publish reports with local daily COVID-19 cases at the level of municipalities or Basic Health Areas).</p> <p>Each record has an identifier, the associated date, the corresponding identifier of the layer and code of the region and a set of COVID-19 related fields, which include the number of new cases (daily incidence) and total cases.</p> <ul> <li> <p><strong>Autonomous Communities</strong>: ES.covid_cca</p> </li> <li> <p><strong>Provinces</strong>: ES.covid_cpro</p> </li> <li> <p>Higher spatial resolution:</p> <ul> <li> <p><strong>Principado de Asturias</strong>: 03.covid_cumun</p> </li> <li> <p><strong>Cantabria</strong>: 06.covid_cumun</p> </li> <li> <p><strong>Castilla y Leon</strong>: 07.covid_abs</p> </li> <li> <p><strong>Cataluña/Catalunya</strong>: 09.covid_abs</p> </li> <li> <p><strong>Comunitat Valenciana</strong>: 10.covid_cumun</p> </li> <li> <p><strong>Comunidad de Madrid</strong>: 13.covid_abs</p> </li> <li> <p><strong>Comunidad Foral de Navarra</strong>: 15.covid_abs</p> </li> <li> <p><strong>País Vasco/Euskadi</strong>: 16.covid_abs</p> </li> </ul> </li> </ul> <p>For information about data sources, visit: <a href="https://flowmaps.life.bsc.es/flowboard/data">https://flowmaps.life.bsc.es/flowboard/data</a></p>
Case report: Papillary squamous cell carcinoma of the penis
<p><strong>Case history</strong></p> <p>62-year-old male with a verruciform tumor located in distal penis and involving glans.</p> <p> </p> <p><strong>Histologic findings</strong></p> <p>The microphotographs show an exophytic verruciform tumor mass characterized by papillomatosis, slight to moderate acanthosis, and hyperkeratosis. Papillae are complex, some with blunt and others with spiky tips. Fibrovascular are present in most but not all papillae and are irregularly shaped. Tumor base is jagged and there is a prominent stromal reaction. Neoplastic cells in papillae and infiltrative tumor nests are well to moderately differentiated (grades 1-2) and no koilocytic atypia is observed.</p> <p> </p> <p><strong>Discussion</strong></p> <p>Verruciform penile tumors comprise about one-quarter of all penile squamous cell carcinomas (SCC) and include papillary, verrucous, and warty carcinomas, as well as giant condylomas and carcinoma cuniculatum. As a group, verruciform carcinomas are characterized by the presence of papillomatosis, acanthosis, and hyperkeratosis. However, there are distinctive morphological features for each one of these tumors. For papillary SCC, the most distinguishing feature is the presence of complex papillae with irregularly shaped fibrovascular cores. Papillary carcinomas tend to be polymorphic with some areas exhibiting condylomatous papillae and others with a more verrucous-like aspect. Fibrovascular cores are readily found in the former and are scant or even absent in the latter.</p> <p>Another important clue in the differential diagnosis with other verruciform tumors is the presence of a jagged tumor-stroma interface. In verrucous and cuniculatum carcinomas the tumor front is broad-based. The absence of koilocytosis allows the distinction from warty carcinomas and giant condylomas, tumors in which koilocytes are conspicuous. HPV status may be helpful in problematic cases, since in papillary carcinomas the HPV detection rate is very low or even null. Immunohistochemistry for p16<sup>INK4a</sup> is also useful since the vast majority of papillary carcinomas do not overexpress this protein. In order for a penile tumor to be considered as p16<sup>INK4a</sup> positive all neoplastic cells should be stained. Cases like this one in which some cells stain and others do not should be regarded as negative for p16<sup>INK4a</sup> overexpression.</p> <p>The inguinal metastatic rate of penile papillary carcinomas is very low and the prognosis is good. Less than one-fifth of all patients present inguinal involvement and even in these cases the mortality rate is low. Even when tumors invade penile erectile tissues prognosis is good as long as no high-grade areas (observed in a minority of the patients) are identified.</p> <p>Clinically patients should be managed using risk-group stratification systems and taking into account histological grade, anatomical level of maximum tumor infiltration, and the presence of vascular and perineural invasion. </p> <p> </p> <p><strong>References</strong></p> <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/20061934">Chaux et al. Am J Surg Pathol. 2010 34(2): 223-30</a></p> <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/22641955">Chaux & Cubilla. Semin Diagn Pathol. 2012 29(2): 72-82</a></p> <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/22641955">Chaux & Cubilla. Semin Diagn Pathol. 2012 29(2): 67-71</a></p>
Demonstration case study reports
<p>As part of the PLAID project an in-depth assessments of the processes involved in achieving efficient and effective on-farm demonstration activities was investigated. 24 year-long studies of demonstration events and activities were selected and followed 2 case studies in each partner country were selected, which followed demonstration from initial commissioning through to impact assessment. The specific objectives were</p> <ul> <li>Improved understanding of the key elements that contribute to successful and effective demonstration activities on commercial farms, looking specifically at: commissioning and financing, topic selection, accessibility, mediation techniques, and embeddedness. Gender will be specifically addressed.</li> <li>Improved understanding of the effectiveness of demonstration activities in terms of learning by participants (at the individual level and the network level: what is learned, by whom, how and why?) and the subsequent impact (i.e. actual implementation of what farmers have learned on their own farm, new network development, innovation inception).</li> <li>Assess the role of demonstration within the wider AKIS systems and what the impact of demonstration is on learning and technology adoption</li> <li>Develop insights into critical success factors, best (and poor) practices, and indicators for effective and successful demonstration activities.</li> </ul>
Phenopackets for case reports of structural variants
<p>A collection of 188 published deleterious structural variants based on 182 cases published in 146 clinical case reports that describe individuals with Mendelian diseases.</p>
Report on Transformers interpretability for Natural Language Processing: A case study on Technical Debt classification
<p>Transformer models have significantly advanced the field of natural language processing (NLP), achieving exceptional results in various tasks. However, these models are often seen as "black boxes", providing limited insight into the factors influencing their predictions. It has become crucial to develop and utilise methods for interpreting and explaining these models to uncover their complex inner workings. This report discusses the latest techniques and tools that aid in a more profound understanding of transformer models within NLP. Additionally, it explores a vital industrial use case: Technical Debt (TD) classification. In this context, the report leverages transformer model interpretability tools and Retrieval Augmented Generation (RAG) to analyse and understand the characteristics of text in Github issues, distinguishing between TD and non-TD.</p> <p>This report thoroughly outlines an approach to improve the transparency and reproducibility of machine learning models, with a special emphasis on TD classification. It integrates the RAG approach and exploits feature attribution techniques, presenting a route to create AI systems that are not only high-performing but also demonstrably trustworthy and comprehensible. Through a detailed examination of word patterns in TD classification and the innovative use of the RAG approach, the research highlights a strong dedication to promoting transparency and responsibility in AI systems, potentially ushering in a new phase in machine learning research that focuses on clarity and dependability.</p>
Synthetic COVID-19 Case Reporting Data Generated from an Agent-Based Simulation Model
<p>This is a synthetic case reporting data set for the SARS-CoV-2 epidemic in Austria. The data set statistically reproduces and synthetically augments data on reported cases and was generated with an agent-based simulation model. References to descriptions of the model and the parameterization used to generate the data set is included in the attached PDF file. The data format is described in the README file.</p>
PharmaCoNER corpus: gold standard annotations of Pharmacological Substances, Compounds and proteins in Spanish clinical case reports
<p><strong>Intro:</strong></p><p>The PharmaCoNER corpus (divided into train, dev and test) is a Gold Standard manually annotated dataset used for the the PharmaCoNER shared task posed at BIONLP-ST (at EMNLP). In addition, we include here the PharmaCoNER background set. It contains the train, development and test sets of the two subtasks (subtask-1 and subtask-2) with Gold Standard annotations. In addition, it contains the documents of the background set, without annotations.</p><p>The PharmaCoNER corpus consists of:</p><ul><li>Manually classified clinical case sections derived from Open access Spanish medical publications, named the Spanish Clinical Case Corpus (SPACCC).</li><li>It was manually selected by a practicing oncologist and revised by a clinical documentalist to assure that records were relevant/representative and resembled structure and content relevant to process clinical records.</li><li>The final corpus: 1000 clinical cases 16,504 sentences</li><li>The corpus contains a total of 396,988 words, with an average of 396.2 words per clinical case.</li><li>It covers a range of medical disciplines including oncology, urology, cardiology, pneumology or infections diseases, etc.</li><li>The corpus has been annotated at the mention level by experts in medicinal chemistry and pharmacology following a granular annotation scheme covering four mention types:<ul><li><i>Entity type 1 (NORMALIZABLES)</i>: mentions of chemicals that can be manually normalized to a unique concept identifier (primarily SNOMED-CT).</li><li><i>Entity type 2 (NO_NORMALIZABLES)</i>: mentions of chemicals that could not be normalized manually to a unique concept identifier.</li><li><i>Entity type 3 (PROTEINAS)</i>: mentions of proteins/genes following an adaptation of the BioCreative GPRO track annotation guidelines (includes peptides, peptide hormones & antibodies).</li><li><i>Entity type 4 (UNCLEAR )</i>: cases of general substance class mentions of clinical relevance, including certain pharmaceutical formulations, general treatments, chemotherapy programs, and vaccines.</li><li>Mentions class "<i>UNCLEAR</i>" (not evaluated for the PharmaCoNER track)</li></ul></li></ul><p> </p><p> </p><p><strong>Please, cite: </strong></p><p>A. G. Agirre, M. Marimon, A. Intxaurrondo, O. Rabal, M. Villegas, M. Krallinger, Pharmaconer: Pharmacological substances, compounds and proteins named entity recognition track, in: Proceedings of The 5th Workshop on BioNLP Open Shared Tasks, 2019, pp. 1–10.</p><p> </p><p><strong>Annotation quality</strong></p><p>Inter-annotator agreement: 93% for annotation, 73% for mapping.</p><p>For more information, see the <a href="https://paperswithcode.com/paper/pharmaconer-pharmacological-substances">paper</a>.</p><p> </p><p><strong>Format</strong></p><p>For subtask 1 annotations are distributed in <i>Brat</i> format. (More info at Brat webpage https://brat.nlplab.org/standoff.html)</p><p>For subtask-2, codes are associated with each document are given in a <i>TSV</i> file with the following columns: </p><blockquote><p>filename code</p></blockquote><p> </p><p><strong>Shared task goal:</strong></p><p>In the two subtasks, the goal is to predict the annotations of the test files (either the ANN files or the TSV with the codes) given only the plain text files. </p><p> </p><p><strong>Resources:</strong></p><ul><li><a href="https://temu.bsc.es/pharmaconer/"><strong>Web</strong></a></li><li><a href="https://www.aclweb.org/anthology/D19-5701.pdf"><strong>Citation</strong></a><strong>: </strong>A. G. Agirre, M. Marimon, A. Intxaurrondo, O. Rabal, M. Villegas, M. Krallinger, Pharmaconer: Pharmacological substances, compounds and proteins named entity recognition track, in: Proceedings of The 5th Workshop on BioNLP Open Shared Tasks, 2019, pp. 1–10.</li><li><a href="https://doi.org/10.5281/zenodo.4271908"><strong>Silver Standard corpus</strong></a></li><li><a href="https://doi.org/10.5281/zenodo.3763276"><strong>Annotation guidelines</strong></a></li><li><a href="https://github.com/TeMU-BSC/PharmaCoNER-Tagger"><strong>PharmaCoNER tagger</strong></a></li><li><a href="https://www.youtube.com/watch?v=B3ZzJl5OMkY"><strong>Youtube video(general setting)</strong></a></li><li><a href="https://www.slideshare.net/MartinKrallinger/pharmaconer-pharmacological-substances-compounds-and-proteins-named-entity-recognition-track-at-bionlpost-workshop-november-4-skycity-rm-2-hong-kong-emnlp2019"><strong>Slides PharmacoNER overview talk at BIONLP-ST / EMNLP </strong></a></li></ul><p>For further information, please visit <a href="https://temu.bsc.es/pharmaconer/">https://temu.bsc.es/pharmaconer/</a> or email us at encargo-pln-life@bsc.es</p><p>Copyright (c) 2018 Secretaría de Estado para el Avance Digital (SEAD)</p><p> </p><p><strong>License</strong></p><p>This work is licensed under a <a href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</a>.</p><p> </p><p><strong>Contact</strong></p><p>If you have any questions or suggestions, please contact us at:</p><p><br>- Martin Krallinger (<krallinger [dot] martin [at] gmail [dot] com>)</p><p><strong>Additional resources and corpora</strong></p><p>If you are interested in PharmaCoNER, you might want to check out these corpora and resources:</p><ul><li><a href="https://zenodo.org/records/7614764">DisTEMIST</a> (Corpus of disease mentions and normalization to SNOMED CT, same document collection)</li><li><a href="https://zenodo.org/records/8224056">MedProcNER </a>(Corpus of clinical procedure mentions and normalization to SNOMED CT, same document collection)</li><li><a href="https://zenodo.org/records/8413866">SympTEMIST</a> (Corpus of symptoms, signs and findings mentions and normalization, same document collection)</li><li><a href="https://zenodo.org/records/7116201">MEDDOPROF</a> (Corpus of mentions of professions, occupations and working status and normalization, different document collection with some overlapping documents)</li><li><a href="https://zenodo.org/records/8403498">MEDDOPLACE</a> (Corpus of mentions of place-related entity mentions, including departments, nationalities or patient movements etc.. and normalization, different document collection with some overlapping documents)</li><li><a href="https://zenodo.org/records/4279323">MEDDOCAN</a> (Corpus of mentions of Personal Health Identifiers (PHI), modified synthetic verions of the document collection)</li><li><a href="https://zenodo.org/records/3978041">CANTEMIST</a> (Corpus of cancer tumor morphology mentions and normalization, different document collection)</li><li><a href="https://zenodo.org/records/3837305">CodiESp</a> (Corpus of clinical case reportes with assigned clinical codes from ICD10, Spanish version, same document collection)</li><li><a href="https://zenodo.org/records/7684093">LivingNER</a> (Corpus of mentions of species, including human/family members, pathogens, food, etc.. and normalization to NCBI Taxonomy, different document collection with some overlapping documents)</li><li><a href="https://zenodo.org/records/2560344">SPACCC-POS</a> (Corpus of clinical case reports in Spanish annotated with POS-tags, same document collection)</li><li><a href="https://zenodo.org/records/2560338">SPACCC-TOKEN</a> (Corpus of clinical case reports in Spanish annotated with token-tags (word mention boundaries), same document collection)</li><li><a href="https://zenodo.org/records/2560338">SPACCC-SPLIT</a> (Corpus of clinical case reports in Spanish annotated with sentence boundary-tags, same document collection)</li><li><a href="https://zenodo.org/records/5602914">MESINESP-2</a> (Corpus of manually indexed records with DeCS /MeSH terms comprising scientific literature abstracts, clinical trials, and patent abstracts, different document collection)</li></ul>
MEDDOCAN corpus: gold standard annotations for Medical Document Anonymization on Spanish clinical case reports
<p><strong>Intro:</strong></p> <p>Meddocan shared task dataset (divided in train, dev and test). In addition, we include here the Meddocan background set.</p> <p>It contains the training, development and test sets of the Meddocan shared task with Gold Standard annotations.</p> <p>In addition, it contains the documents of the background set, without annotations.</p> <p> </p> <p><strong>Annotation quality</strong></p> <p>Inter-annotator agreement: 98% </p> <p>For more information, see the <a href="http://ceur-ws.org/Vol-2421/MEDDOCAN_overview.pdf">paper</a>. </p> <p> </p> <p><strong>Format:</strong></p> <p>Annotations are distributed in Brat format. See <a href="https://brat.nlplab.org/standoff.html">Brat webpage</a> for more information.</p> <p>In addition, annotations are also distributed in XML format (based on i2b2 XML format).</p> <p>In the <a href="https://temu.bsc.es/meddocan/index.php/resources/">Meddocan webpage</a>, there is a script to convert between MEDDOCAN-Brat, MEDDOCAN-XML, and i2b2 formats.</p> <p> </p> <p><strong>Shared task goal:</strong></p> <p>In the three subtasks, the goal will be to predict the annotations given only the plain text files. </p> <p> </p> <p><strong>Resources:</strong></p> <ul> <li><strong><a href="https://temu.bsc.es/meddocan/">Web</a></strong></li> <li><strong>Citation: </strong>Montserrat Marimon et al. “Automatic De-identification of Medical Texts in Spanish: the MEDDOCAN Track, Corpus, Guidelines, Methods and Evaluation of Results.” In: IberLEF@ SEPLN. 2019, pp. 618–638.</li> <li><strong>Silver Standard corpus</strong></li> <li><a href="https://doi.org/10.5281/zenodo.4279337"><strong>Annotation guidelines</strong></a></li> </ul> <p> </p> <p>For further information, please visit <a href="https://temu.bsc.es/meddocan/">https://temu.bsc.es/meddocan/</a> or email us at encargo-pln-life@bsc.es</p> <p>Copyright (c) 2019 Secretaría de Estado para el Avance Digital (SEAD)</p>
A Chinese female Morvan patient with LGI1 and CASPR2 antibodies: a case report
<p>Figure 1-2 of the case and the original photos under fluorescence microscope. Fig. 1 Cranial MRI of our patient. Fig. 2 The immunoreactivity of patient’s serum to CASPR2 and LGI1 proteins.</p>
Statistical data collected in the case studies of the SPOT report - dataset
<p>Statistical data was collected for fifteen case studies in the context of the SPOT project, funded by the European Commission within the framework programme Horizon 2020.</p>
Text-fig. 2. Kaolin clay pit at hill Hasenberg in Wiesa, Saxony, Germany; view of southern high wall, showing deeply weathered late Early Miocene lignite seam by dark brown color in center (photographed 2015). Fossil-bearing strata were reported (e.g., Mai 1964) as below lignite seam, but this horizon does actually not crop out (also evidenced by new drillings, communicated by Dr. Jochen Rascher, GEOMONTAN GmbH company, Freiberg/Sa., Germany). in Assessment Of Phytogeographic Reference Regions For Cenozoic Vegetation: A Case Study On The Miocene Flora Of Wiesa (Germany)
Text-fig. 2. Kaolin clay pit at hill Hasenberg in Wiesa, Saxony, Germany; view of southern high wall, showing deeply weathered late Early Miocene lignite seam by dark brown color in center (photographed 2015). Fossil-bearing strata were reported (e.g., Mai 1964) as below lignite seam, but this horizon does actually not crop out (also evidenced by new drillings, communicated by Dr. Jochen Rascher, GEOMONTAN GmbH company, Freiberg/Sa., Germany).
Figure 1 in Myxobolus spp. (Cnidaria: Myxobolidae) in the circulating blood of fishes from Goiás and Mato Grosso States, Brazil: case report
Figure 1. Blood smears of Myxobolus spp. parasites in the circulating blood of fishes from Goiás State and Mato Grosso State, Brazil (A-D): (A) Morphological type 1 (M1) of Myxobolus sp. in the blood of Tetragonopterus araguaiensis; (B-D) Morphological type 2 (M2) of Myxobolus sp. in the blood of Myleus rubriprinnis (b) and Pygocentrus nattereri (c-d). Polar capsule (PC); Sporoplasm (SP).
Fig. 3 in Cases of albinism and leucism in amphibians in Italy: new reports
Fig. 3 - Leucistic individual of Hydromantes sarrabusensis (A), H. flavus (B) and H. supramontis (C).
Fig. 1 in Cases of albinism and leucism in amphibians in Italy: new reports
Fig. 1 - Fire salamander (Salamandra salamandra) individuals showing albinism and leucism. A) metamorphosed albino with xanthophores found in 2013; B) metamorphosed albino with xanthophores found in 2014; C, D) leucistic adults.
Fig. 2 in Cases of albinism and leucism in amphibians in Italy: new reports
Fig. 2 - Different stages of larval development and metamorphosis of an albino fire salamander larva with xanthophores. A) Moment of collection in November 2014 (40 mm of total length); B) December 2014; C) January 2015; D) pre-metamorphosis on February 15, 2015; E) just after metamorphosis on February 22, 2015.
Case report: Large-cell calcifying Sertoli cell tumor
<p><strong>Case history</strong></p> <p>21-year-old male with a painless mass in the right testicle and a prior history of cutaneous lesions.</p> <p> </p> <p><strong>Histologic findings</strong></p> <p>Figures show a proliferation composed of large, polygonal cells with ample, eosinophilic cytoplasm, round nuclei, evident nucleoli, with a trabecular, cord-like pattern of growth, associated with foci of dystrophic calcification and psammomatous bodies, within a myxoid loose stroma.</p> <p> </p> <p><strong>Discussion</strong></p> <p>Large-cell calcifying Sertoli cell tumor is an unusual morphological variant of Sertoli cell tumors composed of large polygonal Sertoli cells associated with calcification. Around one third of all cases appear in patients with the Carney or, less frequently, with the Peutz-Jeghers syndrome.</p> <p>Clinically, it presents as a small (<2 cm), painless testicular mass, which can be bilateral and multifocal in about 40% of the cases, especially in syndromic settings. In non-sporadic cases extratesticular manifestations are related to the associated syndrome, such as myxomas of the skin, soft-tissue, and heart and myxoid lesions of the breast, facial lentigines, cutaneous blue nevi, secondary Cushing syndrome due to pigmented adrenocortical nodular hyperplasia, pituitary somatotroph adenomas, and psammomatous melanotic schwannomas.</p> <p>Microscopically, solid, tubular, and cord-like growth patterns can be observed. Tumor cells are large polygonal with abundant eosinophilic, finely granular cytoplasm, vesicular nuclei with prominent nucleoli, within a myxohyaline stroma. Distinct calcifications characterized by large, laminated calcified nodule, psammoma bodies and focal ossification, and neutrophilic infiltration, can be also found.</p> <p>The presence of large tumor size (>4 cm), overt nuclear atypias, increased mitotic activity (>3 mitosis/10 HPF), necrosis, extratesticular extension, and vascular invasion are associated with clinical aggressive behavior. Malignant tumors appear in patients older than 25 years old and are usually not associated with syndromes.</p> <p>Tumor cells are positive for vimentin, S-100, EMA, melan-A, desmin, and inhibin, and focally positive for cytokeratins. The main differential diagnoses of large-cell calcifying Sertoli cell tumor include Sertoli cell and Leydig cell tumors.</p> <p>Most of the cases behave indolently, and surgical excision is the treatment of choice.</p>
Case report: Adenosquamous carcinoma of the penis
<p><strong>Case history</strong></p> <p>55-year-old patient with a penile tumor located in the perimeatal area of the glans</p> <p> </p> <p><strong>Histologic findings</strong></p> <p>Microphotographs show a biphasic proliferation of tumors cells showing squamous and glandular differentiation, deeply infiltrating penile erectile tissues. Squamous and glandular structures are found either segregated or in the same tumor nests.</p> <p> </p> <p><strong>Discussion</strong></p> <p>Adenosquamous carcinoma is a rare penile SCC variant characterized by the presence of solid squamous tumor nests intermingled with areas of glandular differentiation. Less than 20 cases have been reported. The tumor originates in the glans central/perimeatal region and has a tendency for deep infiltration. Most tumors are of high-grade, with frequent vascular and perineural invasion. Metastatic rate is high but cancer-specific mortality remains low.</p> <p>Histologically, areas with squamous differentiation predominate. The glandular component is positive for mucin stains and CEA.</p> <p>The main differential diagnosis is with penile tumors with glandular features, including mucoepidermoid, pseudoglandular, urothelial carcinomas of distal urethra with glandular differentiation and true adenocarcinomas of Littré glands. Mucoepidermoid carcinoma of penis is an exceedingly rare tumor which is histologically similar to its cervical counterpart. Neoplastic population is composed of cell with squamous differentiation and cells showing evidence of glandular differentiation (pale, granular and ample cytoplasm with positivity for mucin stains and CEA) without well-defined glandular or ductal structures. Although more data are needed, it seems that mucoepidermoid carcinoma is more aggressive than conventional adenosquamous carcinoma.</p> <p>In pseudoglandular carcinoma the extensive acantholysis can simulate glands lumina but there is no true epithelial lining. Urothelial carcinomas originating in the penile distal urethra or extending from prostate, bladder or even ureter/renal pelvis, can depict glandular features. However, a previous history of urothelial carcinoma elsewhere and the frequent finding of in situ urothelial carcinoma (which is absent in adenosquamous carcinoma) aid in the differential diagnosis.</p> <p>In adenocarcinomas originating in Littré glands there is no true squamous differentiation and tumors tend to be ventrally located with only secondary extension to the perimeatal glans area. Finally, entrapment of Littré’s glans by an otherwise usual SCC can simulate the aspect of an adenosquamous carcinoma. However, the morphology of the glandular component remains bland and admixtures are limited to the periurethral area.</p> <p> </p> <p><strong>Selected references</strong></p> <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/22641956">Chaux & Cubilla. Semin Diagn Pathol. 2012 29(2): 72-82</a></p> <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/8554104">Cubilla et al. Am J Surg Pathol. 1996 20(2): 156-60</a></p> <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/16924331">Romero et al. Clinics (Sao Paulo). 2006 61(4): 363-4</a></p>
Fig. 4 in First Report of a Case of Prostatitis Due to Acanthamoeba in a Dog
Fig. 4. Phylogenetical analysis of the DF3 sequence of the Acanthamoeba strain isolated from the prostate revealed that the strain belonged to genotype T4.
Figure 1 in Anatrachyntis badia (Hodges, 1962) (Lepidoptera: Cosmopterigidae): the first report from Turkey and a case of importation to Poland
Figure 1. Distribution of Anatrachyntis badia (Hodges, 1962) in Europe (the new records are marked by a red dot; the crosshatched areas represent countries where the species was previously recorded; the blank areas represent countries without any records of the species in question; the arrows depict the ways of importation).
Figure 2 in Anatrachyntis badia (Hodges, 1962) (Lepidoptera: Cosmopterigidae): the first report from Turkey and a case of importation to Poland
Figure 2. Male genitalia of Anatrachyntis badia (Hodges, 1962): a- lateral view of a whole structure; b- left anellus lobe (nomenclature follows Zimmerman (1978)).
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.